相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Surgical Complications in a Multicenter Randomized Trial Comparing Preoperative Chemoradiotherapy and Immediate Surgery in Patients With Resectable and Borderline Resectable Pancreatic Cancer (PREOPANC Trial)
Jelle C. van Dongen et al.
ANNALS OF SURGERY (2022)
Impact of Borderline Resectability in Pancreatic Head Cancer on Patient Survival: Biology Matters According to the New International Consensus Criteria
Friedrich Anger et al.
ANNALS OF SURGICAL ONCOLOGY (2021)
Cancer Statistics, 2021
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Alliance A021501: Preoperative mFOLFIRINOX or mFOLFIRINOX plus hypofractionated radiation therapy (RT) for borderline resectable (BR) adenocarcinoma of the pancreas.
Matthew H. G. Katz et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma A Phase 2 Randomized Clinical Trial
Davendra P. S. Sohal et al.
JAMA ONCOLOGY (2021)
Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial
Q. P. Janssen et al.
BMC CANCER (2021)
Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial
Eva Versteijne et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Neoadjuvant or Adjuvant Therapy for Resectable or Borderline Resectable Pancreatic Cancer: Which Is Preferred?
Eileen M. O'Reilly et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Neoadjuvant chemotherapy for primary resectable pancreatic cancer: a systematic review and meta-analysis
Mao Ye et al.
HPB (2020)
Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer
Quisette P. Janssen et al.
FRONTIERS IN ONCOLOGY (2020)
ESPAC-5F: Four-arm, prospective, multicenter, international randomized phase II trial of immediate surgery compared with neoadjuvant gemcitabine plus capecitabine (GEMCAP) or FOLFIRINOX or chemoradiotherapy (CRT) in patients with borderline resectable pancreatic cancer.
Paula Ghaneh et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
The Complexity of Neoadjuvant Therapy for Operable Pancreatic Cancer: Lessons Learned From SWOG S1505
Douglas B. Evans
ANNALS OF SURGERY (2020)
Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP-05).
Michiaki Unno et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis
Quisette P. Janssen et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)
Neoadjuvant therapy versus upfront surgery in resectable pancreatic cancer according to intention-to-treat and per-protocol analysis: A systematic review and meta-analysis
Yoon Suk Lee et al.
SCIENTIFIC REPORTS (2019)
Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer
E. Versteijne et al.
BRITISH JOURNAL OF SURGERY (2018)
International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017
Shuji Isaji et al.
PANCREATOLOGY (2018)
Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study)
Lilian Schwarz et al.
BMC CANCER (2018)
Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018
J. Ferlay et al.
EUROPEAN JOURNAL OF CANCER (2018)
Diagnosis and management of pancreatic cancer in adults: A summary of guidelines from the UK National Institute for Health and Care Excellence
Derek O'Reilly et al.
PANCREATOLOGY (2018)
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
T. Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial-1 (NorPACT-1)) - study protocol for a national multicentre randomized controlled trial
Knut Jorgen Labori et al.
BMC SURGERY (2017)
Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas
Matthew H. G. Katz et al.
BMC CANCER (2017)
The use of adjuvant chemotherapy for pancreatic cancer varies widely between hospitals: a nationwide population-based analysis
Maikel J. Bakens et al.
CANCER MEDICINE (2016)
Neoadjuvant Chemoradiotherapy and Surgery Versus Surgery Alone in Resectable Pancreatic Cancer: A Single-Center Prospective, Randomized, Controlled Trial Which Failed to Achieve Accrual Targets
Riccardo Casadei et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2015)
Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer
Henriette Golcher et al.
STRAHLENTHERAPIE UND ONKOLOGIE (2015)
Postoperative Complications Reduce Adjuvant Chemotherapy Use in Resectable Pancreatic Cancer
Ryan P. Merkow et al.
ANNALS OF SURGERY (2014)
Management of Patients with Pancreatic Adenocarcinoma: National Trends in Patient Selection, Operative Management, and Use of Adjuvant Therapy
Skye C. Mayo et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2012)
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Julian P. T. Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection Percentages
Sonja Gillen et al.
PLOS MEDICINE (2010)
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
Alessandro Liberati et al.
ANNALS OF INTERNAL MEDICINE (2009)
GRADE:: an emerging consensus on rating quality of evidence and strength of recommendations
Gordon H. Guyatt et al.
BRITISH MEDICAL JOURNAL (2008)
Practical methods for incorporating summary time-to-event data into meta-analysis
Jayne F. Tierney et al.
TRIALS (2007)
分享论文
